You just read:

Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

News provided by

Jazz Pharmaceuticals plc

25 Mar, 2020, 20:05 GMT